Article Sidebar

Published: 2026-08-14
Abstract Views: 0
DOI: https://doi.org/10.52163/yhc.v67iCD12.6139
Issue
Tập 67 Số CĐ12- HNKH Bệnh viện Ung bướu Nghệ An
Section
Articles
How to Cite
Trang, N. T., Hằng, V. T., & Hương, L. T. L. (2026). EFFICACY OF ADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND 5-FLUOROURACIL IN STAGE II-III GASTRIC CANCER PATIENTS AT THANH HOA ONCOLOGY HOSPITAL. Vietnam Journal of Community Medicine, 67(CD12). https://doi.org/10.52163/yhc.v67iCD12.6139

EFFICACY OF ADJUVANT CHEMOTHERAPY WITH OXALIPLATIN AND 5-FLUOROURACIL IN STAGE II-III GASTRIC CANCER PATIENTS AT THANH HOA ONCOLOGY HOSPITAL

Nguyen Thi Trang1, Vu Thi Hang2, Le Thi Lan Huong3
1 MSc, MD, Department of Internal Medicine 1 – Oncology Hospital
2 MSc, Specialist Level II Doctor – Head of Internal Medicine Department 1, UBTH Hospital
3 Physician, Department of Internal Medicine 1 – UBTH Hospital

Main Article Content

Abstract

Objective: To evaluate the outcomes and adverse effects of the adjuvant Oxaliplatin – 5FU regimen in stage II–III gastric cancer patients at Thanh Hoa Oncology Hospital. Patients and Methods: A retrospective descriptive study was conducted on 45 patients with stage II–III gastric cancer who underwent radical surgery followed by adjuvant Oxaliplatin – 5FU chemotherapy from January 2022 to August 2025 at Thanh Hoa Oncology Hospital. Results: The mean study period was 23 ± 7.89 months. The 3-year overall survival (OS) rate was 73.1%, with a mean overall survival time of 34.63 ± 1.47 months. The 3-year disease-free survival (DFS) rate was 54.7%, with a mean disease-free survival time of 30.87 ± 1.80 months. Adverse effects were predominantly grades 1–2. Conclusion: The adjuvant Oxaliplatin – 5FU regimen for stage II–III gastric cancer at Thanh Hoa Oncology Hospital is safe and effective.

Article Details

Keywords

Stage II–III gastric cancer; Adjuvant chemotherapy; Oxaliplatin – 5FU.

References

1. Đỗ Thị Hằng. Kết quả điều trị bổ trợ bệnh nhân ung thư dạ dàygiai đoạn II, III bằng phác đồ XELOX tại BVĐK tỉnh Vĩnh Phúc. Luận văn Thạc sỹ. Đại Học Y Hà Nội; 2023
2. Lê Thị Thu Nga. Đánh giá kết quả điều trị hóa chất bổ trợ phác đồ XELOX sau phẫu thuật ung thư dạ dày, Luận Văn tiến sĩ. Đại Học Y Hà Nội; 2022.
3. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial - The Lancet. Accessed September 30, 2024. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(11)61873-4/abstract
4. Adjuvant Chemotherapy for Gastric Cancer with S-1, an Oral Fluoropyrimidine | New England Journal of Medicine. Accessed September 30, 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa072252
5. Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer | New England Journal of Medicine. Accessed September 30, 2024. https://www.nejm.org/doi/full/10.1056/nejmoa073149
6. Cancer (IARC) TIA for R on. Global Cancer Observatory. Accessed September 22, 2024. https://gco.iarc.fr/
7. Impact of Adjuvant FOLFOX on Quality of Life and Peripheral Neuropathy Incidence in Patients With Gastric Cancer: A Prospective Cohort Study. Value Health Reg Issues. 2023;35:13-18. doi:10.1016/j.vhri.2022.12.005
8. Ke B, Song XN, Liu N, Zhang RP, Wang CL, Liang H. Prognostic value of the lymph node ratio in stage III gastric cancer patients undergoing radical resection. PloS One. 2014;9(5):e96455. doi:10.1371/journal.pone.0096455
9. Phase II study of adjuvant chemotherapy of S-1 plus oxaliplatin for patients with stage III gastric cancer after D2 gastrectomy | Gastric Cancer. Accessed September 30, 2024. https://link.springer.com/article/10.1007/s10120-015-0581-1
10. Zhang XL, Shi HJ, Cui SZ, Tang YQ, Ba MC. Prospective, randomized trial comparing 5-FU/LV with or without oxaliplatin as adjuvant treatment following curative resection of gastric adenocarcinoma. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2011;37(6):466-472. doi:10.1016/j.ejso.2011.01.027